Spruce Biosciences, Inc. (NASDAQ: SPRB) is a Healthcare company (Biotechnology) with a market capitalization of $116M. The Maz Rating grades it against the other companies in its sector.
Spruce Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $40.49, Spruce Biosciences, Inc. trades at 1.7x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -118.2%, return on invested capital of -82.0% and a free cash flow yield of -44.0%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 4.83. Over the past 52 weeks the share price ranged from $38.06 to $127.90, with a beta of 3.54.
Spruce Biosciences, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 7 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Spruce Biosciences, Inc. (SPRB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.46% / 30% · (Cash+Inv) / Mkt Cap (36m) 72.4% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 6.46% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 72.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 6.46% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 72.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 7.03% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 8.51% / 33.33% · (Cash+ST Inv) / Total Assets 95.4% / 33.33% · (Cash+Recv) / Total Assets 95.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Spruce Biosciences, Inc. (SPRB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Spruce Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Spruce Biosciences, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.